Cure8 research brief
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this biologic.
Adult patients with moderate-to-severe ulcerative colitis, gastroenterologists and IBD clinicians considering vedolizumab, and researchers studying predictors of biologic response.
This retrospective multicenter study from northern China included 184 patients with moderate-to-severe UC treated with vedolizumab and examined baseline nutritional scores alongside routine blood biomarkers.
GNRI showed the strongest correlation and the highest discriminatory ability (AUC 0.697) for predicting 14-week clinical remission; PNI and MUST were also associated. By later follow-up (weeks 30 and 54), only baseline hemoglobin remained independently associated with remission.
The findings suggest that lower nutritional risk (higher GNRI/PNI, lower MUST) may be linked to a greater chance of early clinical response to vedolizumab, but longer-term predictors differed. These results are hypothesis-generating and reflect associations from an observational, retrospective cohort rather than randomized evidence.
Retrospective design and single-region multicenter sample limit causal inference and broad generalizability; results should be validated prospectively in diverse populations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
